UMLS. CSP-HL7-ICD9CM-NCI-NDFRT-RXNORM
%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
D D D- D0 D1 D2 D5 D7 D8 D9 DA DB DC DD DE DF DG DH DI DJ DK DL DM DN DO DP DR DS DT DU DV DW DX DY
DI DIA DIB DIC DID DIE DIF DIG DIH DII DIK DIL DIM DIN DIO DIP DIQ DIR DIS DIT DIU DIV DIZ
selected terms: 296 page 1 of 3

1. 1,2 diazole
[5-membered aromatic ring structure with 2 adjacent nitrogen heteroatoms. ( CSP )] (UMLS (CSP) C0072662) =Organic Chemical ;
=azole;
=antipyrine
51. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with ophthalmic manifestations
[ ] (UMLS (ICD9CM) C0375134) =Disease or Syndrome
2. 1,2,5,6 dianhydrogalactitol
[A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04) ( NCI )] (UMLS (NCI) C0011967) =Carbohydrate; Pharmacologic Substance ;
52. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with other specified manifestations
[ ] (UMLS (ICD9CM) C0375145) =Disease or Syndrome
3. 1,2-diammino-methy lcyclobutane-platinum (II) lactate
[An anticancer drug that belongs to the family of drugs called platinum compounds. ( NCI )] (UMLS (NCI) C0165747) =Organic Chemical; Pharmacologic Substance
53. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders
[ ] (UMLS (ICD9CM) C0375141) =Disease or Syndrome
4. 1,3 diazine
[ ] (UMLS (CSP) C0034284) =Organic Chemical ;
54. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with renal manifestations
[ ] (UMLS (ICD9CM) C0375130) =Disease or Syndrome
5. 1,3-Diamino-4-methoxybenzene Sulphate
[A synthetic, off-white to violet solid that is soluble in water and ethanol. It is used primarily as a component of oxidizing 'permanent' hair- and fur-dye formulations. 2,4-Diaminoanisole sulfate is also used as an intermediate in the production of C.I. Basic Brown 2, a dye commonly used in numerous consumer products. The primary routes of potential human exposure to 2,4-diaminoanisole sulfate are dermal contact and inhalation. It is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0126603) =Organic Chemical; Pharmacologic Substance
55. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with unspecified complication
[ ] (UMLS (ICD9CM) C0375149) =Disease or Syndrome
6. 1,3-Diamino-4-methylbenzene
[A synthetic, colorless to brown crystalline solid that is soluble in water, ethanol, ether and benzene. It is used primarily as an intermediate in the production of toluene diisocyanate, which is used to produce polyurethane. Small amounts of 2,4-diaminotoluene are also used to produce dyes for textiles, leathers, furs, and wood and biological stains. When heated to decomposition, it emits toxic fumes of nitrogen oxides. The primary routes of potential human exposure to 2,4-diaminotoluene are dermal contact and inhalation. Contact with this chemical can irritate the eyes and skin. It is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0045479) =Organic Chemical; Hazardous or Poisonous Substance ;
56. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with neurological manifestations
[ ] (UMLS (ICD9CM) C0375139) =Disease or Syndrome
7. 1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl
[A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04) ( NCI )] (UMLS (NCI) C0075019) =Organic Chemical; Pharmacologic Substance ;
57. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with ophthalmic manifestations
[ ] (UMLS (ICD9CM) C0376128) =Disease or Syndrome
8. 1,3-Diaziridino-2,4,6-Triaza-1,3,5,5-Tetraaminomethyl-1,3,5-Triphosphorin
[An aziridinyl-substituted cyclophosphazene and a putrescence derivative that may cause DNA cross-linkage. (NCI04) ( NCI )] (UMLS (NCI) C0043914) =Organic Chemical; Pharmacologic Substance ;
58. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with other specified manifestations
[ ] (UMLS (ICD9CM) C0375147) =Disease or Syndrome
9. 1,4 diazine
[ ] (UMLS (CSP) C0677630) =Organic Chemical
59. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with peripheral circulatory disorders
[ ] (UMLS (ICD9CM) C0375143) =Disease or Syndrome
10. 1,4-Diamino-2,3-dicyano-1,4- bis(2-aminophynyltio)butadiene
(UMLS (NCI) C0755559) Bis[amino[(2-aminophenyl)thio]methylene]butanedinitrile =Organic Chemical; Pharmacologic Substance ;
60. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with renal manifestations
[ ] (UMLS (ICD9CM) C0375132) =Disease or Syndrome
11. 1,4:3,6-Dianhydro-D-glucitol 5-nitrate
[The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05) ( NCI )] (UMLS (NCI) C0064079) =Organic Chemical; Pharmacologic Substance ;
=ISOSORBIDE;
ISOSORBIDE DINITRATE =ISOSORBIDE MONONITRATE 120 MG;
ISOSORBIDE MONONITRATE 10 MG;
ISOSORBIDE MONONITRATE 20 MG;
ISOSORBIDE MONONITRATE 60 MG;
ISOSORBIDE MONONITRATE 30 MG
61. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with unspecified complication
[ ] (UMLS (ICD9CM) C0375151) =Disease or Syndrome
12. 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
[antibacterial used in combination with a sulfonamide to treat some urinary tract infections and pneumocystis pneumonia, and alone as an antimalarial. ( CSP )] (UMLS (NCI) C0041041) =Organic Chemical; Pharmacologic Substance ;
=Pyrimidine;
antibacterial agent;
DAP;
[AM900] ANTI-INFECTIVES, OTHER =2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine Sulfate (2:1);
TRIMETHOPRIM 100 MG;
TRIMETHOPRIM 160 MG;
TRIMETHOPRIM 200 MG;
TRIMETHOPRIM 40 MG/5ML;
TRIMETHOPRIM 16 MG/ML;
TRIMETHOPRIM 80 MG;
TRIMETHOPRIM 50 MG/5ML;
62. Diabetes mellitus with hyperosmolarity
[ ] (UMLS (ICD9CM) C0375121) =Disease or Syndrome
13. 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine Sulfate (2:1)
[The sulfate salt form of trimethoprim, a synthetic substituted pyrimidine with antibacterial activity. Trimethoprim sulfate selectively binds to and reversibly inhibits dihydrofolate reductase, thereby blocking the production of tetrahydrofolic acid from dihydrofolic acid. This leads to an inhibition of bacterial synthesis of folic acid, thereby affecting nucleic acid and protein synthesis. Trimethoprim sulfate has a stronger binding affinity for the bacterial enzyme than for the corresponding mammalian enzyme. ( NCI )] (UMLS (NCI) C0724713) Trimethoprim Sulfate;
TRIMETHOPRIM SULFATE PREPARATION;
=Organic Chemical; Pharmacologic Substance ;
=2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine;
=TRIMETHOPRIM SULFATE 0.1 %
63. Diabetes mellitus with other coma, type I [juvenile type], uncontrolled
[ ] (UMLS (ICD9CM) C0375129) =Disease or Syndrome
14. 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate
[A drug that belongs to the family of drugs called antimetabolites. It is used in the treatment of pneumocystis carinii pneumonia and is being studied in the treatment of cancer. ( NCI )] (UMLS (NCI) C0077209) =Organic Chemical; Pharmacologic Substance ;
64. Diabetes mellitus with other coma, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled
[ ] (UMLS (ICD9CM) C0375128) =Disease or Syndrome
15. 2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine
[An anticancer drug. ( NCI )] (UMLS (NCI) C0054332) =Organic Chemical; Pharmacologic Substance ;
65. Diabetes mellitus without mention of complication
[ ] (UMLS (ICD9CM) C0271635) =Disease or Syndrome
16. 2,6-Diamino-3-(phenylazo)-pyridine Hydrochloride
[A synthetic, brick-red crystalline solid that is only slightly soluble in cold water and ethanol but is soluble in boiling water, acetic acid, glycerol, ethylene glycol and propylene glycol. It is used orally as a urinary tract analgesic. Side effects of phenazopyridine hydrochloride administration can include nausea, interference with the oxygen-carrying capacity of red blood cells (methemoglobinemia), hemolytic anemia as well as renal and hepatic toxicity. It is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0700555) =Organic Chemical; Pharmacologic Substance ;
=PHENAZOPYRIDINE;
=PHENAZOPYRIDINE HYDROCHLORIDE 100 MG;
PHENAZOPYRIDINE HYDROCHLORIDE 200 MG;
PHENAZOPYRIDINE HYDROCHLORIDE 50 MG;
PHENAZOPYRIDINE HYDROCHLORIDE 150 MG;
66. Diabetes mellitus, antepartum
[The state of PREGNANCY in women with DIABETES MELLITUS. This does not include either symptomatic diabetes or GLUCOSE INTOLERANCE induced by pregnancy (DIABETES, GESTATIONAL) which resolves at the end of pregnancy. ( MSH )] (UMLS (ICD9CM) C0032969) =Disease or Syndrome ;
=Diabete mellito;
Pregnancy Complication =fetal macrosomia;
17. 3,12-Diaza-6,9-diazoniadispiro(5.2.5.2)hexadecane, 3,12-bis(3-chloro-2-hydroxypropyl)-, dichloride
[An dispiropiperazine derivative with potential cytostatic, anti-inflammatory and immune-suppressive properties. Although the exact mechanism of action of prospidin is not known, this agent was shown to interact with DNA, disrupting cell cycle at G2 phase, inhibiting phagocytic activity of monocytes and macrophage. Prospidin has good anti-lupus activity due to its immunosuppressive effects and was also used in refractory rheumatoid arthritis as an anti-rheumatic drug. (NCI04) ( NCI )] (UMLS (NCI) C0033524) =Organic Chemical; Pharmacologic Substance
67. Diabetes mellitus, postpartum
[ ] (UMLS (ICD9CM) C0341894) =Disease or Syndrome
18. 3,5-Diacetamido-2,4,6-triiodobenzoic Acid, Sodium Salt
[An iodinated radiopaque X-ray contrast medium. Diatrizoate sodium blocks X-rays, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine and allowing visualization of these areas. This contrast agent is used as a diagnostic aid in angiography, urography and radiography. (NCI05) ( NCI )] (UMLS (NCI) C0012007) =Organic Chemical; Indicator, Reagent, or Diagnostic Aid =3,5-Bis(acetylamino)-2,4,6-triiodobenzoic Acid;
1-Deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (salt) =DIATRIZOATE NA PWDR,ORAL;
DIATRIZOATE SODIUM 80 MG/ML;
DIATRIZOATE SODIUM 100 MG;
DIATRIZOATE SODIUM 8 %;
DIATRIZOATE SODIUM 20 %;
DIATRIZOATE SODIUM 35 %;
DIATRIZOATE SODIUM 50 %;
DIATRIZOATE SODIUM 42 %;
DIATRIZOATE SODIUM 25 %;
DIATRIZOATE SODIUM 10 %;
DIATRIZOATE SODIUM 30 %;
DIATRIZOATE SODIUM 29.1 %
68. Diabetes mellitus, type I [insulin dependent type] [IDDM] [juvenile type] with hyperosmolarity, not stated as uncontrolled
[ ] (UMLS (ICD9CM) C0375123) =Disease or Syndrome
19. 4,4'-Diaminodiphenylsulfide
[A brown to violet colored solid aromatic amine that emits toxic fumes of nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen and sulfur oxides when heated to decomposition. 4,4'-Thiodianiline is primarily used as a chemical intermediate in the production of certain dyes. Exposure to this substance is irritating to the respiratory tract and can result in methemoglobinemia causing headache, dizziness, weakness and can lead to shortness of breath, collapse and even death. 4,4'-Thiodianiline is a possible mutagen and is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0047830) =Organic Chemical; Pharmacologic Substance ;
69. Diabetes mellitus, type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled
[ ] (UMLS (ICD9CM) C0375127) =Disease or Syndrome
20. 4,4'-Diamonophenyl
[A grayish-red, yellowish or white colored, very toxic, crystalline aromatic amine that darkens when exposed to air and light. Benzidine has been widely used for the detection of blood and as a reagent in the manufacture of dyes. Ingestion of benzidine causes cyanosis, headache, mental confusion, nausea and vomiting. Its use is now limited because of strong association between exposure to benzidine and an increased risk of bladder cancer in humans. (NCI05) ( NCI )] (UMLS (NCI) C0005047) =Organic Chemical; Hazardous or Poisonous Substance
70. Diabetes mellitus, type I [juvenile type] with hyperosmolarity, uncontrolled
[ ] (UMLS (ICD9CM) C0375125) =Disease or Syndrome
21. 6-DIAZO-5-OXO-L-NORLEUCINE
[An antibiotic isolated from Streptomyces with potential antineoplastic activity. Diazooxonorleucine inhibits several glutamine-dependent biosynthetic pathways including the synthesis of D-glucosamine phosphate, purines and pyrimidines. As an L-glutamine antagonist, diazooxonorleucine inhibits phosphate-activated glutaminase, thereby interfering with glutamine metabolism, ultimately depleting cells of this essential amino acid and reducing the capacity to proliferate. Another mechanism of action including inhibition of glycoprotein, gamma-guanosine triphosphatease, DNA and RNA synthesis has been proposed. ( NCI )] (UMLS (NCI) C0012020) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
71. Diabetes mellitus, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type with hyperosmolarity, not stated as uncontrolled
[ ] (UMLS (ICD9CM) C0375122) =Disease or Syndrome
22. Di-Adreson-F
(UMLS (NCI) C0699539) =Steroid; Pharmacologic Substance
72. Diabetes mellitus, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled
[ ] (UMLS (ICD9CM) C0375126) =Disease or Syndrome
23. DIA (differentiation inhibiting activity)
[ ] (UMLS (CSP) C0113865) =Amino Acid, Peptide, or Protein; Immunologic Factor
73. Diabetes mellitustype II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type with hyperosmolarity, uncontrolled
[ ] (UMLS (ICD9CM) C0375124) =Disease or Syndrome
24. diabetes amputation
[ ] (UMLS (CSP) C0598284) =Therapeutic or Preventive Procedure
74. diabetes prevention
[ ] (UMLS (CSP) C1659987) =Educational Activity ;
25. diabetes bronze
[condition in which there is a deviation or interruption in the storage of iron in the body. ( CSP )] (UMLS (CSP) C0018995) =Disease or Syndrome =DIS IRON METABOLISM;
inborn metal metabolism disorder;
iron overload;
=hemosiderosis;
75. diabetes risk
[factors that affect the probability or may predisposition of an individual to the development of diabetes mellitus and its associated complications. ( CSP )] (UMLS (CSP) C1171304) =Quantitative Concept ;
=diathesis;
26. diabetes education
[instruction or training that encourages behaviors most likely to optimize health potentials through information about diabetes; facilitates the prevention of diabetes, frequently for those who are at risk for developing diabetes; also includes instruction or training that increases the awareness and favorably influences the attitudes and knowledge about diabetes on a personal or community basis; it also includes the training of medical personnel about diabetes for prevention or treatment programs, for this type of diabetes education postcoordinate with the appropriate health professional education term. ( CSP )] (UMLS (CSP) C0850356) =Educational Activity =health education;
76. Diabetes with ketoacidosis
[complication of diabetes resulting from severe insulin deficiency coupled with an absolute or relative increase in glucagon concentration; metabolic acidosis is caused by the breakdown of adipose stores and resulting increased levels of free fatty acids; glucagon accelerates the oxidation of the free fatty acids producing excess ketone bodies (ketosis). ( CSP )] (UMLS (ICD9CM) C0011880) =Disease or Syndrome =acidosis;
Diabete mellito
27. Diabetes Educator
(UMLS (HL7) C1555973) =Intellectual Product =Registered Nurse;
77. Diabetes with neurological manifestations
[common complication of diabetes mellitus in which nerves are damaged as a result of hyperglycemia (high blood sugar levels). ( CSP )] (UMLS (ICD9CM) C0011882) =Disease or Syndrome =Diabete mellito;
DISORDERS OF THE PERIPHERAL NERVOUS SYSTEM =Diabetic Foot;
28. DIABETES IN PREG-UNSPEC
[ ] (UMLS (ICD9CM) C0341893) =Disease or Syndrome
78. Diabetes with ophthalmic manifestations
(UMLS (ICD9CM) C0342245) =Disease or Syndrome ;
29. Diabetes in Pregnancy
[glucose intolerance which onsets during pregnancy; does not include diabetics who become pregnant or women who become lactosuric; after pregnancy, the woman is reclassified as diabetic or not depending on whether glucose intolerance persists. ( CSP )] (UMLS (NCI) C0085207) =Disease or Syndrome ;
=Diabete mellito;
Pregnancy Complication;
Pregnancy Disorder;
=fetal macrosomia
79. Diabetes with other coma
(UMLS (ICD9CM) C0011870) =Disease or Syndrome
30. diabetes insipidus
[metabolic disorder due to injury of the neurohypophyseal system; results in deficient quanity of antidiuretic hormone being released or produced, failure of tubular reabsorption of water in the kidney. ( CSP )] (UMLS (CSP) C0011848) =Disease or Syndrome =hypopituitarism;
Metabolic Disease =Diabetes Insipidus, Nephrogenic;
Wolfram syndrome;
Diabetes Insipidus, Nephrogenic;
antidiuretic hormone defective syndrome
80. Diabetes with other specified manifestations
(UMLS (ICD9CM) C0154183) =Disease or Syndrome
31. Diabetes mellitus
[heterogeneous group of disorders that share glucose intolerance in common.(CSP)] (UMLS (ICPC) C0011849) (Diabetes mellitus; DIABETES MELITUSA; Diabetes mellitus; Diabetes mellitus; SOKERITAUTI; Diabete sucre; Diabetes mellitus; sukeret; diabetes mellitus; Diabete mellito; SUKKERSYKE/DIABETES MELLITUS; Diabetes mellitus; Diabetes mellitus; DIABETES MELLITUS/SOCKERSJUKA) =Disease or Syndrome =Endocrine Disease; Metabolic Disease; Endocrine Pancreas Disease; ENDOCRINE, METABOLIC AND NUTRITIONAL; Diagnosis/Diseases Component; =Diabetes Mellitus, Insulin-Dependent; adult onset diabetes mellitus; Diabetic Angiopathies; Diabetes with ketoacidosis; Diabetes with renal manifestations; Diabetes with neurological manifestations; Diabetes in Pregnancy; drug related diabetes mellitus; prediabetic state; virus related diabetes mellitus; diabetic cardiomyopathy; diabetic ophthalmopathy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Lipoatrophic; adult onset diabetes mellitus; Diabetic Angiopathies; Diabetes with ketoacidosis; Diabetes with renal manifestations; Diabetes with neurological manifestations; Obesity in Diabetes; Diabetes mellitus, antepartum; Diabetes in Pregnancy; prediabetic state; diabetic coma;
81. Diabetes with peripheral circulatory disorders
(UMLS (ICD9CM) C0011871) =Disease or Syndrome
32. diabetes mellitus diet
[A diet that uses carbohydrates sparingly. Typically with a restriction in daily energy content (e.g. 1600-2000 kcal). ( HL7V3.0 )] (UMLS (HL7) C1550566) =Intellectual Product =Diet;
82. Diabetes with renal manifestations
[kidney disease and resultant kidney function impairment due to the long standing effects of diabetes on the microvasculature (glomerulus) of the kidney; features include increased urine protein and declining kidney function. ( CSP )] (UMLS (ICD9CM) C0011881) =Disease or Syndrome =Diabete mellito;
Kidney Disease
33. diabetes mellitus genetics
[heredity of diabetes mellitus, especially the mechanisms of hereditary transmission and the variation of inherited characteristics of diabetes mellitus; the genetic constitution of an individual as it relates to diabetes mellitus. ( CSP )] (UMLS (CSP) C0596425) =Occupation or Discipline =Genetics;
83. Diabetes with unspecified complication
[Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. ( MSH )] (UMLS (ICD9CM) C0342257) =Pathologic Function ;
34. diabetes mellitus nursing
[ ] (UMLS (CSP) C0599003) =Biomedical Occupation or Discipline ;
84. Diabetic Autonomic Neuropathy
(UMLS (NCI) C0271686) =Disease or Syndrome
35. Diabetes mellitus of mother, with delivery
[ ] (UMLS (ICD9CM) C0341897) =Disease or Syndrome
85. diabetic cardiomyopathy
[complication of diabetes that affects the structure and function of the heart. ( CSP )] (UMLS (CSP) C0853897) =Disease or Syndrome ;
=Diabete mellito;
cardiomyopathy
36. Diabetes mellitus of mother, with delivery, with mention of postpartum complication
[ ] (UMLS (ICD9CM) C0341896) =Disease or Syndrome
86. diabetic cataract
[rare, usually bilateral, opacity shaped like a snowflake, affecting the anterior and posterior cortices of young diabetics; sometimes it can be reversed when the blood glucose is brought under control, but in most cases it progresses rapidly to a mature cataract. ( CSP )] (UMLS (CSP) C0011876) =Acquired Abnormality; Disease or Syndrome ;
=cataract;
diabetic ophthalmopathy
37. diabetes mellitus therapy
[ ] (UMLS (CSP) C0948092) =Therapeutic or Preventive Procedure =Therapeutic Interventions;
=artificial endocrine pancreas
87. diabetic coma
[A state of unconsciousness as a complication of diabetes mellitus. It occurs in cases of extreme HYPERGLYCEMIA or extreme HYPOGLYCEMIA as a complication of INSULIN therapy. ( MSH )] (UMLS (CSP) C1263960) =Disease or Syndrome =Diabete mellito;
=Hyperglycemic Hyperosmolar Nonketotic Coma;
38. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with neurological manifestations
[ ] (UMLS (ICD9CM) C0375138) =Disease or Syndrome
88. DIABETIC MACULAR EDEMA
[ ] (UMLS (ICD9CM) C0730285) =Disease or Syndrome
39. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with ophthalmic manifestations
[ ] (UMLS (ICD9CM) C0375135) =Disease or Syndrome
89. diabetic ophthalmopathy
[pathologic changes of the eye due to a severe complication of diabetes mellitus. ( CSP )] (UMLS (CSP) C0920358) =Disease or Syndrome =Diabete mellito;
Disorder of eye, unspecified =diabetic cataract;
diabetic retinopathy;
40. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with other specified manifestations
[ ] (UMLS (ICD9CM) C0375146) =Disease or Syndrome
90. diabetic retinopathy
[retinal changes occurring in diabetes mellitus, marked by microaneurysms, exudates, and hemorrhages, and sometimes by neovascularization. ( CSP )] (UMLS (CSP) C0011884) =Disease or Syndrome =Diabetic Angiopathies;
ANDRE NETTHINNESYKDOMMER - h35.0;
diabetic ophthalmopathy;
41. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with peripheral circulatory disorders
[ ] (UMLS (ICD9CM) C0375142) =Disease or Syndrome
91. Diabinese
(UMLS (NCI) C0591359) =Organic Chemical; Pharmacologic Substance
42. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with renal manifestations
[ ] (UMLS (ICD9CM) C0375131) =Disease or Syndrome
92. DIABP
[The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. ( NCI )] (UMLS (NCI) C0428883) =Clinical Attribute
43. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with unspecified complication
[ ] (UMLS (ICD9CM) C0375150) =Disease or Syndrome
93. Diacarb
(UMLS (NCI) C0699248) =Organic Chemical; Pharmacologic Substance ;
44. Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled, with unspecified complication
[ ] (UMLS (ICD9CM) C0375152) =Disease or Syndrome
94. diacetylmorphine
[narcotic analgesic drug prepared from morphine, now prohibited in the United States even for medicinal uses because of the danger of addiction. ( CSP )] (UMLS (CSP) C0011892) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance =MORPHINE;
45. Diabetes mellitus type I [juvenile type], uncontrolled, with neurological manifestations
[ ] (UMLS (ICD9CM) C0375140) =Disease or Syndrome
95. diadic interaction
[a relationship between two individuals; e.g., marriage. ( CSP )] (UMLS (CSP) C0596467) =Social Behavior =interpersonal relations;
46. Diabetes mellitus type I [juvenile type], uncontrolled, with ophthalmic manifestations
[ ] (UMLS (ICD9CM) C0375136) =Disease or Syndrome
96. Diagnosed
[general term for detecting and classifying diseases. ( CSP )] (UMLS (NCI) C0011900) =Health Care Activity =technology/technique;
=cardiovascular disorder diagnosis;
CAD;
ear disorder diagnosis;
endocrine disorder diagnosis;
eye disorder diagnosis;
respiratory disorder diagnosis;
urinary tract disorder diagnosis;
mass screening;
antepartum diagnosis;
diagnostic test;
diagnosis quality/standard;
noninvasive diagnosis;
biliary tract disorder diagnosis;
blood disorder diagnosis;
communicable disease diagnosis;
connective tissue disorder diagnosis;
early detection;
gastrointestinal disorder diagnosis;
genetic disorder diagnosis;
immunopathology diagnosis;
liver disorder diagnosis;
mental disorder diagnosis;
metabolism disorder diagnosis;
neoplasm/cancer diagnosis;
nervous system disorder diagnosis;
nutrition disorder diagnosis;
parasitic disease diagnosis;
radiodiagnosis;
rapid diagnosis;
reproductive system disorder diagnosis;
skin disorder diagnosis;
speech disorder diagnosis;
communication disorder diagnosis;
musculoskeletal disorder diagnosis
47. Diabetes mellitus type I [juvenile type], uncontrolled, with other specified manifestations
[ ] (UMLS (ICD9CM) C0375148) =Disease or Syndrome
97. Diagnosis
(UMLS (HL7) C1546899) =Classification =Diagnosis Classification;
48. Diabetes mellitus type I [juvenile type], uncontrolled, with peripheral circulatory disorders
[ ] (UMLS (ICD9CM) C0375144) =Disease or Syndrome
98. Diagnosis (US)
[high frequency sound waves used to identify and examine internal organs and structures without the invasive hazards of X xays, dyes, or fluoroscopy. ( CSP )] (UMLS (NCI) C0041618) =Diagnostic Procedure =imaging/visualization/scanning;
Modality;
ObservationMethod;
=Diagnostic ultrasound of heart;
ultrasound echoencephalography;
angiocardioultrasonography;
ultrasound blood flow measurement;
49. Diabetes mellitus type I [juvenile type], uncontrolled, with renal manifestations
[ ] (UMLS (ICD9CM) C0375133) =Disease or Syndrome
99. Diagnosis and age conflict
(UMLS (HL7) C1547462) =Intellectual Product =OCE Edit Code;
50. Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with neurological manifestations
[ ] (UMLS (ICD9CM) C0375137) =Disease or Syndrome
100. Diagnosis and sex conflict
(UMLS (HL7) C1547473) =Intellectual Product =OCE Edit Code;

Buy website

Medical Clinic. Optician. Pharmacy. Physician. Travel Agency. Hotel reservation. Child Care. Education. Teachers. Lessons. Tests and Exams. Certification. Shopping Center. Store. Real Estate.
Affordable prices from $100.


 home Dictionaries Armenian-English English-Armenian MeSH Feedback  top
© 2008 -2011 Administrator MEDINDEX.AM